Advertisement

Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

      Highlights

      • Evolocumab showed better efficacy in patients with acute coronary syndrome
      • Evolocumab resulted in substantial reduction in LDL cholesterol levels
      • The benefits of evolocumab were consistent across the major subgroups

      ABSTRACT

      Purpose

      Evolocumab has been shown to improve cardiovascular outcomes in patients with stable atherosclerotic disease. Whether this benefit persists in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) remains undetermined. This study aimed to evaluate the efficacy and safety of the early initiation of evolocumab in Chinese patients with ACS undergoing PCI.

      Methods

      This retrospective cohort study involved 1564 consecutive patients who had been hospitalized with ACS and underwent PCI, and who had elevated LDL-C levels (≥1.8 mmol/L after receiving high-intensity statin therapy for ≥4 weeks; ≥2.3 mmol/L after receiving low- or moderate-intensity statin; or ≥3.2 mmol/L without statin therapy). Patients who received evolocumab (initiated in-hospital and after 18 months) were included in the evolocumab group (n = 414), and all other patients were included in the control group (n = 1150). The primary outcome at 18 months was a composite of ischemic stroke, cardiovascular death, myocardial infarction, hospitalization for unstable angina, or coronary revascularization. The evolocumab treatment effect on the primary outcome was assessed in all prespecified subgroups.

      Findings

      At 18 months, evolocumab combined with statins reduced LDL-C levels from baseline levels by 42.48% compared with statins alone. After multivariable adjustment, evolocumab combined with statins significantly reduced the primary outcome (8.2% vs 12.4%; adjusted hazard ratio, 0.65; 95% CI, 0.45–0.95; P = 0.025). In addition, evolocumab consistently reduced the primary outcome across the major subgroups. For the safety outcomes, no significant differences between the groups were observed in any adverse events.

      Implications

      Among Chinese patients who underwent PCI for ACS, the early initiation of evolocumab combined with statin treatment effectively reduced LDL-C levels and lowered the incidence of recurrent ischemic cardiovascular events, with satisfactory tolerability and safety. Chinese Clinical Trial Registry identifier: ChiCTR2100049364.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fox KA
        • Goodman SG
        • Klein W
        • et al.
        Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE).
        Eur Heart J. 2002; 23: 1177-1189
        • Jernberg T
        • Hasvold P
        • Henriksson M
        • Hjelm H
        • Thuresson M
        • Janzon M.
        Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.
        Eur Heart J. 2015; 36: 1163-1170
        • Roffi M
        • Patrono C
        • Collet JP
        • et al.
        2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
        Eur Heart J. 2016; 37: 267-315
        • Ference BA
        • Ginsberg HN
        • Graham I
        • et al.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
        Eur Heart J. 2017; 38: 2459-2472
        • Collins R
        • Reith C
        • Emberson J
        • et al.
        Interpretation of the evidence for the efficacy and safety of statin therapy.
        Lancet. 2016; 388: 2532-2561
        • Koskinas KC
        • Siontis GCM
        • Piccolo R
        • et al.
        Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
        Eur Heart J. 2018; 39: 1172-1180
        • Descamps OS
        • Fraass U
        • Dent R
        • Marz W
        • Gouni-Berthold I.
        Anti-PCSK9 antibodies for hypercholesterolaemia: overview of clinical data and implications for primary care.
        Int J Clin Pract. 2017; : 71
        • Mach F
        • Baigent C
        • Catapano AL
        • et al.
        2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
        Eur Heart J. 2020; 41: 111-188
        • Bruckert E
        • Hayem G
        • Dejager S
        • Yau C
        • Begaud B.
        Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study.
        Cardiovasc Drugs Ther. 2005; 19: 403-414
        • Cohen JD
        • Brinton EA
        • Ito MK
        • Jacobson TA.
        Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users.
        J Clin Lipidol. 2012; 6: 208-215
        • Rojas-Fernandez CH
        • Goldstein LB
        • Levey AI
        • Taylor BA
        • Bittner V
        The National Lipid Association's Safety Task Force. An assessment by the Statin Cognitive Safety Task Force: 2014 update.
        J Clin Lipidol. 2014; 8: S5-16
        • HPS2-THRIVE Collaborative Group
        HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
        Eur Heart J. 2013; 34: 1279-1291
        • Dai W
        • Huang XS
        • Zhao SP.
        No evidence to support high-intensity statin in Chinese patients with coronary heart disease.
        Int J Cardiol. 2016; 204: 57-58
        • Gitt AK
        • Lautsch D
        • Ferrieres J
        • et al.
        Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
        Atherosclerosis. 2016; 255: 200-209
        • Zhao S
        • Wang Y
        • Mu Y
        • et al.
        Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
        Atherosclerosis. 2014; 235: 463-469
        • Chiang CE
        • Ferrieres J
        • Gotcheva NN
        • et al.
        Suboptimal control of lipid levels: results from 29 countries participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS).
        J Atheroscler Thromb. 2016; 23: 567-587
        • Jankowski P
        • Czarnecka D
        • Wolfshaut-Wolak R
        • et al.
        Secondary prevention of coronary artery disease in contemporary clinical practice.
        Cardiol J. 2015; 22: 219-226
        • Kotseva K
        • Wood D
        • De Bacquer D
        • et al.
        EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.
        Eur J Prev Cardiol. 2016; 23: 636-648
        • Sabatine MS
        • Giugliano RP
        • Keech A
        • et al.
        Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.
        Am Heart J. 2016; 173: 94-101
        • Sabatine MS
        • Giugliano RP
        • Keech AC
        • et al.
        Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N Engl J Med. 2017; 376: 1713-1722
        • Sabatine MS
        • Giugliano RP
        • Wiviott SD
        • et al.
        Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
        N Engl J Med. 2015; 372: 1500-1509
        • Grundy SM
        • Stone NJ
        • Bailey AL
        • et al.
        2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2019; 73: e285-e350
        • Koskinas KC
        • Windecker S
        • Pedrazzini G
        • et al.
        Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
        J Am Coll Cardiol. 2019; 74: 2452-2462
        • Grundy SM
        • Stone NJ
        • Bailey AL
        • et al.
        2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Circulation. 2019; 139: e1082-e1143
        • Baigent C
        • Blackwell L
        • et al.
        • Cholesterol Treatment Trialists Collaboration
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • LaRosa JC
        • Grundy SM
        • Waters DD
        • et al.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Preiss D
        • Seshasai SR
        • Welsh P
        • et al.
        Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
        JAMA. 2011; 305: 2556-2564
        • Jiang J
        • Zhou YJ
        • Li JJ
        • et al.
        Uncontrolled hyperlipidemia in Chinese patients who experienced acute coronary syndrome: an observational study.
        Ther Clin Risk Manag. 2018; 14: 2255-2264
        • Guedeney P
        • Giustino G
        • Sorrentino S
        • et al.
        Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials [published online ahead of print July 3, 2019].
        Eur Heart J. 2022; 43: e17-e25
        • Nicholls SJ
        • Puri R
        • Anderson T
        • et al.
        Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial.
        JAMA. 2016; 316: 2373-2384
        • Raber L
        • Ueki Y
        • Otsuka T
        • et al.
        Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial [published online ahead of print April 3, 2022].
        JAMA. 2022; 18: 1771-1781